European Guideline on Data Integrity in GCP Studies

The EMA has published “Guideline on computerised systems and electronic data in clinical trials.”

Anyone familiar with Annex 11 of Eudralex Annex 4 won’t be surprised by the content, but frankly I expect a lot of folks who have primarily experience on the clinical side will be scratching their heads. The fact that the authors felt the need to have an entire paragraph dedicated to unique user names is telling.

This is a great resource for sponsors who need to figure out just what to evaluate at investigators sites, a requirement this guideline repeats multiple times.

I’ll be very curious how effective sponsors are in ensuring this requirement is met “The investigator should receive an introduction on how to navigate the audit trail of their own data in order to be able to review changes.”

ASQ FD&C Boston Poster session – 28Feb2023

Yesterday the Food, Drug, and Cosmetic Division of the ASQ hosted a poster session on the question “What are you proud of in your eQMS? What about your implementation or continued use stands out and that you want to share?”

This was our first try and it also happened in one of the few winter weather events we’ve had this season in Boston, but I was incredibly pleased by the turnout and the five posters were all superlative.

I was actually so busy that the only photo I remembered to take was this one, which was actually 10 minutes before our official start time.

There were five posters:

  • Visual Hierarchy (Jeremiah Genest, Amylyx Pharmaceuticals)
  • Smart Numbering & Page Layouts (Kevin Kao, AVROBIO)
  • Minor Deviation Process (Jamie Dupuis, Agios)
  • Supplier Change Notifications – Requirements & Challenges (Russ Jacob, Resilience)
  • Electronic Forms – utilizing templates, tokens, and connectivity (Greg Greene, Amylyx Pharmaceuticals)

I thought each of the posters brought a different bit to the conversation, and wow were there a lot of conversations going on!

I definitely learned that next time I need to get recorded talks from folks. I had originally planned this, but it didn’t happen mostly because I was just too involved in talking about my poster.

I want to say an immense thank you to our very gracious hosts Veeva Systems, who provided a great spot and a whole lot of hospitality. Will Gould was great to work with and really went above-and-beyond as a host.

With the great attendance and the on-the-site feedback, definitely planning on doing this again. A quick survey to gauge interest and help select a topic is here: https://forms.office.com/r/rUf7VRE6Dy

Data Integrity Warning Letter

In July 2022, the U.S. FDA issued a Warning Letter to the U.S. American company “Jost Chemical Co.” after having inspected its site in January 2022. The warning letter listedfour significant areas:

  • Failure of your quality unit to ensure that quality-related complaints are investigated and resolved, and failure to extend investigations to other batches that may have been associated with a specific failure or deviation.”
  • “Failure to establish adequate written procedures for cleaning equipment and its release for use in manufacture of API.”
  • “Failure to ensure that all test procedures are scientifically sound and appropriate to ensure that your API conform to established standards of quality and purity, and failure to ensure laboratory data is complete and attributable.”
  • “Failure to exercise sufficient controls over computerized systems to prevent unauthorized access or changes to data, and failure to establish and follow written procedures for the operation and maintenance of your computerized systems.”

I offer them the above clip as a good mini-training. I recently watched the show, and my wife thought I was going to have several heart attacks.

In a serious nature, please do not short your efforts in data integrity.

Boscon 2022

I am pretty excited that Boscon, the local ASQ section’s conference is back on and calling for proposals. So for local folks, a good time to share some best practices and case studies.


BOSCON is an annual quality conference hosted by ASQ Boston. BOSCON is the New England signature event where national and international quality professionals hear speakers discuss different quality topics and network with them. The conference focus for 2022 is Navigating Quality Performance in a post-Pandemic World (Risk management, Impact/risk & mitigation of pandemic on companies, Work-life balance, Resource management, Employee Safety, Virtual/ remote workspace, Customer satisfaction, Supply chain).

Tracks and possible focus

  • Technical Quality tool (CAPA, 5S, SPC, Lean 6 sigma, etc);
  • IT/Software (Cybersecurity, cloud, virtual workspace, etc);
  • Pandemic Supply Chain (Lean reconsidered, Change management);
  • Personnel/People (Work-life balance, resource management).

Not interested in presenting, but want to participate as a volunteer?
Contact Snehal Rane  Snehalrane90@gmail.com BOSCON 2022 Chair

B0SCON 2022 PRESENTATION PROPOSAL FORM

We invite you to submit your proposal(s) for BOSCON 2022 oriented towards one of the track areas above.  Please provide a concise and clear description of your session topic and the values it provides to our attendees. 50 minutes are provided for your presentation and any Q&A.

KEY DATES

  • August 15th => Please complete the form referenced below and submit to both Snehalrane90@gmail.com and dmanalan@alum.mit.edu as soon as possible, and no later than August 15th.
  • September 1st => Applicants will be notified if the submitted proposal was accepted, confirmation requires a signed speaker agreement.
  • September 15th => Sign speaker agreement and submit.
  • October 1st => Submit final set of slides by October 1st.

Fill out the form- Word version at

https://1drv.ms/w/s!Aq7kI8QOQQN5hD-FL4JLDqGKF8yc?e=USkE6y

Being Small and Speciality Does not Exempt from the GMPs

Specialty Process Labs LLC is a specialty API manufacturer of natural desiccated thyroid. Which is, yes, what you might think it is. And as far I can tell, mostly ships direct to compounding pharmacies and patients. This month they got a warning letter.

The warning letter highlights:

  1. Failure to validate the process
  2. Failure to test to specification
  3. Failure to exercise sufficient controls over computerized systems

All three of these observations make me rather glad my loved-ones take levothyroxine and I am deeply aware of all the difficulties in that drug supply.

Focusing more on the computer system, it is an unsurprising list of bad access controls, change controls not controlled, and failure to validate excel spreadsheets.

The last observation really stood out to me:

Manufacturing master batch records held in electronic form on your company’s shared drive do not have restrictions on user access. Your quality unit personnel stated that there are no restrictions for any personnel with login credentials to access new and obsolete master records. Our investigator observed during the inspection multiple versions of batch records were utilized for API lot production.”

This is truly a failure in document access and record management. And it is one I see a lot of places. The core requirement here is really well stated in the PIC/S Data Integrity Guidance requirement 8.4 “Expectations for the generation, distribution and control of records.” Please read the whole section, but pay close attention to the following:

  • Documents should be stored in a manner which ensures appropriate version control.
  • Master documents should contain distinctive marking so to distinguish the master from a copy, e.g. use of coloured papers or inks so as to prevent inadvertent use.
  • Master documents (in electronic form) should be prevented from unauthorised or inadvertent changes.
  • Document issuance should be controlled by written procedures that include the following controls:
    • details of who issued the copies and when they were issued; clear means of differentiating approved copies of documents, e.g. by use of a secure stamp, or paper colour code not available in the working areas or another appropriate system;
    • ensuring that only the current approved version is available for use;
    • allocating a unique identifier to each blank document issued and recording the issue of each document in a register; – numbering every distributed copy (e.g.: copy 2 of 2) and sequential numbering of issued pages in bound books;
    • where the re-issue of additional copies of the blank template is necessary, a controlled process regarding re-issue should be followed with all distributed copies maintained and a justification and approval for the need of an extra copy recorded, e.g.: “the original template record was damaged”;
    • critical GMP/GDP blank forms (e.g.: worksheets, laboratory notebooks, batch records, control records) should be reconciled following use to ensure the accuracy and completeness of records; and
    • where copies of documents other than records, (e.g. procedures), are printed for reference only, reconciliation may not be required, providing the documents are time-stamped on generation, and their short-term validity marked on the document

There are incredibly clear guidelines for these activities that the agencies have provided. Just need to use them.